General Information

Subsidy Information and Financing Scheme
MAF

Regorafenib Tablet 40 mg


1) Treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal...
MSHL

Regorafenib Tablet 40 mg


1) Treatment of patients with metastatic colorectal cancer who have been previously treated with, o...
Drug Guidance for Subsidy

02/01/2024 Review of cancer drugs for previously treated advanced hepatocellular carcinoma

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Cabozantinib 20 mg, 40 mg a...

19/12/2022 Regorafenib and trifluridine/tipiracil for previously treated metastatic colorectal cancer

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Regorafenib 40 mg tablet fo...

19/12/2022 Review of cancer drugs for previously treated advanced gastric cancer

The Ministry of Health’s Drug Advisory Committee has recommended:

  • Nivolumab 40 mg/4 mL and 10...
General Availability in Public Healthcare Institution
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration

Registered Product(s) Information

Please select a product for clinical info:

Please select a Registered Product for product info.